Skip to content
Peptigraph home
Shop Peptides50% off*

KLOW for Injury Recovery: What the Evidence Shows

What human and animal studies show about KLOW for injury recovery, how strong that evidence is, and what is still unproven.

Medical review pendingFour-peptide blendUpdated
Strongest evidence
Human RCT
from an ingredient's studies
Human studies
2
with an outcome for injury recovery, in our evidence file (PubMed search, 11 Oct 2026)
Animal studies
19
with an outcome for injury recovery, in our evidence file (PubMed search, 11 Oct 2026)
Studies we summarised
26
with an outcome for injury recovery

Evidence for injury recovery

Each row is an outcome related to injury recovery from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here. No study has tested KLOW itself; rows are for each ingredient.

KLOW for injury recovery: outcomes in published studies
OutcomeResultStudy typeSource
TB-500: Wound healingPhase 2 findings suggest a 0.03% dose may accelerate healing, with complete healing within 3 months in about 25% of patients, mainly those with smaller or milder ulcers.Human RCTn = 73Annals of the New York Academy of Sciences 2010, PMID 20536470
GHK-Cu: Plantar ulcer closureMedian ulcer area closure was 98.5% with the GHK-copper gel versus 60.8% with vehicle (p < 0.05).Human RCTWound repair and regeneration 1994, PMID 17147644
GHK-Cu: Ulcer infectionUlcer infections occurred in 7% with the gel versus 34% with vehicle among ulcers treated immediately after debridement (p < 0.05).Human RCTWound repair and regeneration 1994, PMID 17147644
BPC-157: Evidence base sizeOnly 1 of 36 included studies was clinical; 35 were preclinical.Systematic reviewHSS journal 2025, PMID 40756949
BPC-157: Musculoskeletal outcomes in preclinical modelsPreclinical models showed improved outcomes in muscle, tendon, ligament and bone injury.Systematic reviewHSS journal 2025, PMID 40756949
TB-500: Phase 2 wound trialsThe review reports accelerated repair in phase 2 trials of pressure ulcers, stasis ulcers and epidermolysis bullosa wounds.ReviewVitamins and hormones 2016, PMID 27450738
BPC-157: Maximum load to failure (BPC-157)Maximum load to failure was higher with BPC-157 than controls, but the difference was significant only in the TB-500 group (p < 0.05).Animal · rat (not a human result)n = 32Joint diseases and related surgery 2026, PMID 42542926
BPC-157: Tendon histology (BPC-157)BPC-157 alone gave numerically lower tendon degeneration scores that did not reach statistical significance.Animal · rat (not a human result)n = 32Joint diseases and related surgery 2026, PMID 42542926
TB-500: Maximum load to failure (TB-500)Maximum load to failure was higher in both the BPC-157 and TB-500 groups than controls; the difference reached significance only for TB-500 (p < 0.05).Animal · rat (not a human result)n = 32Joint diseases and related surgery 2026, PMID 42542926
TB-500: Combination vs single agentCombining BPC-157 and TB-500 gave no additional benefit over either alone.Animal · rat (not a human result)n = 32Joint diseases and related surgery 2026, PMID 42542926
TB-500: Corneal alkali burnThe peptide-containing hydrogel accelerated corneal epithelial regeneration and reduced inflammation in an alkali burn model; this is a formulation study.Animal · human corneal cells in vitro plus an animal alkali burn model (species not stated in abstract) (not a human result)ACS applied materials & interfaces 2025, PMID 41359360
BPC-157: Spinal cord injury recoveryRats treated with BPC 157 after spinal cord injury showed clinical improvement, better tail motor function and resolved spasticity by day 15.Animal · rat (not a human result)Journal of orthopaedic surgery and research 2019, PMID 31266512
GHK-Cu: Scald wound healing timeWound healing time was shortened to 14 days with GHK-Cu liposomes in mice.Animal · mouse (plus human umbilical vein endothelial cells) (not a human result)Wound repair and regeneration 2017, PMID 28370978
GHK-Cu: Knee laxityKnee laxity was smaller with GHK-Cu at 6 weeks (p = 0.009) but not significantly different at 12 weeks.Animal · rat (not a human result)n = 72Journal of orthopaedic research 2015, PMID 25731775
TB-500: Neurological recovery after strokeNeurological outcome improved significantly at 2 and 12 mg/kg from day 14, extending to day 56.Animal · rat (not a human result)n = 10Journal of the neurological sciences 2014, PMID 25060418
TB-500: Highest doseThe higher dose (18 mg/kg) did not show significant improvement, so the dose response was not linear.Animal · rat (not a human result)n = 10Journal of the neurological sciences 2014, PMID 25060418
BPC-157: Colitis and anastomosis healingControl rats did not heal; BPC 157 induced healing of both cysteamine colitis and colon-colon anastomosis.Animal · rat (not a human result)Journal of physiology and pharmacology 2013, PMID 24304574
TB-500: Ligament healingLocal thymosin beta-4 improved ligament healing histologically and mechanically in rats.Animal · rat (not a human result)Regulatory peptides 2013, PMID 23523891
BPC-157: Ligament healingBPC 157-treated rats showed consistent functional, biomechanical, macroscopic and histological healing improvements.Animal · rat (not a human result)Journal of orthopaedic research 2010, PMID 20225319
BPC-157: Muscle healing despite corticosteroidBPC 157 reversed the corticosteroid-impaired muscle healing in this rat injury model.Animal · rat (not a human result)Medical science monitor 2010, PMID 20190676

Showing the first 20 of 33 rows, strongest sources first.

KLOW and injury recovery are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 11 Oct 2026). Grades follow our .

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4TB-500: Annals of the New York Academy of Sciences 2010, PMID 20536470

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Sports injuries and the treatments MedlinePlus lists

MedlinePlus names rest, ice, compression and elevation as the usual first treatment for a sports injury.[15]

Healing outcomes for each component

GHK-Cu gel was tested on diabetic foot ulcers in a placebo-controlled trial, with a higher closure rate than vehicle.[2]

In mice with scalds, GHK-Cu in liposomes was followed by a healing time of 14 days.[8]

In a rat model of ACL reconstruction, GHK-Cu injections improved knee laxity at 6 weeks, but not at the later check.[9]

BPC-157 helped tendon fibroblasts in the lab to move and survive stress, and the proposed pathway is FAK-paxillin.[16]

A review of BPC-157 summarizes animal gains in muscle, tendon, ligament and bone injuries.[3]

The TB500 sequence in a hydrogel sped epithelial regrowth in a corneal burn model, an injury model and not a sports injury.[6]

A search matching all four components together returned 0 PubMed records on 2 Oct 2026, so the blend has no injury-recovery study.

Calculated from search GHK-Cu terms AND BPC-157 terms AND (TB-500 OR thymosin beta-4 terms) AND KPV terms; date 2026-10-02; count 0; page topic injury recovery; source our combinations data ghk-cu__klow. Formula: records matching all four components = count = 0

Other peptides people research for injury recovery

BPC-157TirzepatideHGHWolverineTB-500GHK-CuGLOWLL-37

Common questions

Does KLOW help with injury recovery?

The strongest study we summarise for injury recovery is human rct evidence, for an ingredient rather than the blend, across 26 studies with an outcome for injury recovery. A trial result is not an approval; see the legal status.

Is KLOW approved for injury recovery?

No. KLOW is not FDA approved for any use, including injury recovery.

Does KLOW speed injury recovery?

Healing results are for individual components in rodents or in single-product human trials.[2]

More on KLOW

DosageDoses used in published studies, with the source for each.Blend calculatorSplit a blend vial into per-peptide amounts and units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.

Sources

  1. 1The effect of thymosin treatment of venous ulcers.Annals of the New York Academy of Sciences · 2010PMID 20536470Accessed 2 Oct 2026
  2. 2Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 1994PMID 17147644Accessed 2 Oct 2026
  3. 3Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025PMID 40756949Accessed 2 Oct 2026
  4. 4Thymosin β4 Promotes Dermal Healing.Vitamins and hormones · 2016PMID 27450738Accessed 2 Oct 2026
  5. 5Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
  6. 6Alkaline Phosphatase-Triggered Spatiotemporal Repair of Corneal Injury with TB500 Peptide Hydrogel.ACS applied materials & interfaces · 2025PMID 41359360Accessed 2 Oct 2026
  7. 7Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats.Journal of orthopaedic surgery and research · 2019PMID 31266512Accessed 2 Oct 2026
  8. 8GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2017PMID 28370978Accessed 2 Oct 2026
  9. 9Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2015PMID 25731775Accessed 2 Oct 2026
  10. 10A dose-response study of thymosin β4 for the treatment of acute stroke.Journal of the neurological sciences · 2014PMID 25060418Accessed 2 Oct 2026
  11. 11Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability.Journal of physiology and pharmacology : an official journal of the Polish Physiological Society · 2013PMID 24304574Accessed 2 Oct 2026
  12. 12Thymosin β4 enhances the healing of medial collateral ligament injury in rat.Regulatory peptides · 2013PMID 23523891Accessed 2 Oct 2026
  13. 13Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2010PMID 20225319Accessed 2 Oct 2026
  14. 14Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application.Medical science monitor : international medical journal of experimental and clinical research · 2010PMID 20190676Accessed 2 Oct 2026
  15. 15Official web pageOfficial web page · web page
  16. 16The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.Journal of applied physiology (Bethesda, Md. : 1985) · 2011PMID 21030672Accessed 2 Oct 2026

Found an error? Report a correction.